Related Experiment Video
Updated: Sep 10, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Prognostic Value of Circulating Tumor DNA (ctDNA) in Diffuse Large B-Cell Lymphoma (DLBCL): Systematic Review and
Anu Kumari1, Anupriya Kaur2, Charanpreet Singh1
1Department of Clinical Hematology & Medical Oncology, PGIMER, Chandigarh, India.
Abstract:
Circulating cell-free DNA (ccf-DNA) and circulating tumor DNA (ctDNA) provide a minimally invasive method for cancer detection and measurement. However, their diagnostic and prognostic significance in hematological malignancies remains ambiguous. This meta-analysis aims to evaluate the prognostic value of ccf-DNA or ctDNA in patients with diffuse large B-cell lymphoma (DLBCL). All relevant literature was retrieved through a systematic search of electronic databases, including PubMed, Embase, Scopus, and the Cochrane Library. Eight eligible studies were selected for the analysis of prognostic value of ccf-DNA or ctDNA. Statistical analyses were performed using R software. The results indicate significant associations with both PFS (HR = 2.14; 95% CI: 1.31-3.40; p < 0.01) and OS (HR = 2.51; 95% CI: 1.84-3.40) for patients with elevated ccf-DNA or ctDNA levels. The results of this meta-analysis strongly suggest that elevated levels of ccfDNA or ctDNA are indicative of poor prognosis in patients with DLBCL.
Supplementary Information:
The online version contains supplementary material available at https://doi.org/10.1007/s12288-025-02234-1.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018